Compare COO & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COO | RVMD |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Ophthalmic Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 19.1B |
| IPO Year | 1994 | N/A |
| Metric | COO | RVMD |
|---|---|---|
| Price | $71.40 | $98.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 17 |
| Target Price | $90.18 | ★ $120.47 |
| AVG Volume (30 Days) | ★ 1.9M | 1.6M |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $2,532,800,000.00 | N/A |
| Revenue This Year | $6.66 | N/A |
| Revenue Next Year | $5.20 | $408.69 |
| P/E Ratio | $108.35 | ★ N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $61.78 | $29.17 |
| 52 Week High | $89.83 | $124.49 |
| Indicator | COO | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.36 | 52.84 |
| Support Level | $70.97 | $93.86 |
| Resistance Level | $75.24 | $107.45 |
| Average True Range (ATR) | 1.73 | 3.13 |
| MACD | 0.26 | 0.06 |
| Stochastic Oscillator | 58.35 | 76.31 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.